In non-hematopoietic cancers, protection of MKPs against chemotherapy-induced cytotoxicity via the administration of hematopoietic cytokines (Stem Cell Factor [SCF], Interleukin 11 [IL-11] and thrombopoietin receptor agonists) has been previously proposed76–78. Here, MPL is linked to hematopoietic and lymphoid cell neoplasm.